152 filings
Page 7 of 8
8-K
xallyt
7 Mar 16
Entry into a Material Definitive Agreement
12:00am
8-K
33ouwzja62cdngnmz7do
2 Mar 16
Revance Releases Fourth Quarter and Full Year 2015 Results
12:00am
8-K
3zaayernhza
12 Feb 16
Departure of Directors or Certain Officers
12:00am
8-K
fw0u05vmghv 5yub3
7 Jan 16
Results of Operations and Financial Condition
12:00am
8-K
y986x3ik ah
23 Dec 15
Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis
12:00am
8-K
cozl5p2p9ho yry
14 Dec 15
Departure of Directors or Certain Officers
12:00am
8-K
lgex5q
9 Nov 15
Revance Therapeutics Releases Third Quarter 2015 Results
12:00am
8-K
r72r4ct
4 Nov 15
Entry into a Material Definitive Agreement
12:00am
8-K
lrii8 tf2bsr
2 Nov 15
Results of Operations and Financial Condition
12:00am
8-K
qx5x1 897dl
29 Oct 15
Regulation FD Disclosure
12:00am
8-K
shw71zez
6 Aug 15
Revance Therapeutics Releases Second Quarter 2015 Results
12:00am
8-K
0th8csy
2 Jul 15
Departure of Directors or Certain Officers
12:00am
8-K
35zc 0yrbto
3 Jun 15
Revance Therapeutics to Initiate Two Key Trials for RT001, its Topical
12:00am
8-K
vluav6a9sefvw6p4y7x
13 May 15
Revance Therapeutics Releases First Quarter 2015 Financial Results
12:00am
8-K
7cq8clo0jt3k
13 May 15
Departure of Directors or Certain Officers
12:00am
8-K
6lq5js0eomb35giae1kl
4 May 15
Other Events
12:00am
8-K
nxkl3syma6kbzn
2 Mar 15
Revance Therapeutics Releases Fourth Quarter and Full Year 2014
12:00am
8-K
7bnc46lj2it il
27 Feb 15
Revance Appoints Dr. Philip Vickers to its Board of Directors
12:00am
8-K
f8sdf 76z
3 Feb 15
Departure of Directors or Certain Officers
12:00am
8-K
bt1nr8
12 Jan 15
Results of Operations and Financial Condition
12:00am